AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34824124
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 3 g of fosfomycin
Trial: 34824124
Drug: 2 days of
RxNorm normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 days of 3 g of fosfomycin o.d.
Trial: 34824124
Drug: 3 days of
RxNorm normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 days of pivmecillinam 400 mg three times per day (t.i.d)
Trial: 34824124
Drug: 5 days of
RxNorm normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 days of nitrofurantoin 100 mg t.i.d.
Trial: 34824133
Drug: Perfusion-guided endovascular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perfusion-guided endovascular super-selective intra-arterial infusion of mesenchymal stem cells loaded with Delta-24 (MSC-D24)
Trial: 34824133
Drug: Perfusion-guided endovascular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perfusion-guided endovascular super-selective intra-arterial infusion of MSC-D24
Trial: 34824596
Drug: Janssen Ad26.COV2.S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Janssen Ad26.COV2.S vaccine
Trial: 34826114
Drug: SHP465 mixed
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHP465 mixed amphetamine salts (MAS) 6.25 mg once daily for 28 days
Trial: 34826122
Drug: FLECTOR (diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FLECTOR (diclofenac epolamine topical system)
Trial: 34826412
Drug: Pola-G-Len (polatuzumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pola-G-Len (polatuzumab vedotin 1.4 mg/kg + lenalidomide 20 mg + obinutuzumab 1000 mg)
Trial: 34829796
Drug: PARP Inhibitors
RxNorm normalized name: Poly (ADP-ribose) polymerase (PARP) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PARP Inhibitors
Trial: 34829967
Drug: Oral bacteriotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral bacteriotherapy (Vivomixx® in EU, Visbiome® in USA) for 6 months
Trial: 34831051
Drug: Lp(a) levels
RxNorm normalized name: LP-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lp(a) levels <30 mg/dL
Trial: 34831051
Drug: Lp(a) levels
RxNorm normalized name: LP-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lp(a) levels ≥30 mg/dL
Trial: 34831332
Drug: Mild prolonged
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mild prolonged hypoglycemia (blood glucose maintained at 2.8 mmol/L for 1 hour)
Trial: 34834511
Drug: Salmeterol/Fluticasone Fixed-Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol/Fluticasone Fixed-Dose Combination (SFC) via Elpenhaler for 12 months
Trial: 34835197
Drug: ERUCoV-VAC (whole-virion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ERUCoV-VAC (whole-virion inactivated SARS-CoV-2 vaccine candidate)
Trial: 34836907
Drug: Brief Contact
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief Contact Interventions (BCIs) monthly
Trial: 34836907
Drug: Brief Contact
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief Contact Interventions (BCIs) weekly
Trial: 34836908
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy (DAPT) and high-intensity statins (atorvastatin or rosuvastatin) within 24 hours of stroke onset, followed by aspirin or clopidogrel alone from day 22.
Trial: 34836908
Drug: Single antiplatelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single antiplatelet therapy without high-intensity statin treatment (historical control).
Trial: 34837382
Drug: Roselle extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roselle extract capsules (total dose of 5600 mg)
Trial: 34837553
Drug: High-flow nasal
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flow nasal cannula (HFNC) therapy set at 40 L/min and titrated based on improvement in ROX index and patient tolerance.
Trial: 34837553
Drug: HFNC flow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HFNC flow set at 45 L/min at enrollment.
Trial: 34838114
Drug: S-ketamine (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-ketamine (0.2 mg/kg)
Trial: 34838114
Drug: S-ketamine (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-ketamine (0.4 mg/kg)
Trial: 34838114
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment without S-ketamine
Trial: 34838125
Drug: Metacognitive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metacognitive therapy (MCT) and work-focused interventions
Trial: 34838717
Drug: Oral HPV
RxNorm normalized name: Adxs hpv
DrugBank: Axalimogene filolisbac (DB16692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral HPV prevalence measured using a commercially available PCR DNA test.
Trial: 34839055
Drug: Home-based intensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based intensive chemotherapy
Trial: 34839199
Drug: EMI-137 (0.13
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EMI-137 (0.13 mg/kg) administered intravenously 1-3 hours before surgery
Trial: 34839196
Drug: Infant's medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infant's medication number at hospital discharge
Trial: 34839196
Drug: Medications number
RxNorm normalized name: Derma Numb
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medications number at hospital discharge
Trial: 34839425
Drug: Implant Reconstruction
RxNorm normalized name: CONSTRICTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant Reconstruction
Trial: 34840651
Drug: Oral glutathione
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glutathione supplement (L-glutathione, ascorbic acid, alpha-lipoic acid, zinc as zinc aspartate)
Trial: 34840720
Drug: Talazoparib (0.1-2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Talazoparib (0.1-2.0 mg once daily)
Trial: 34841093
Drug: PIRATES approach
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PIRATES approach (intensity-modulated proton therapy, mid-treatment hybrid hyper-fractionation, MRI-guided mid-treatment boost volume adaptation, iso-effective restricted organ-at-risk dosing)
Trial: 34842060
Drug: Virtual group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual group therapy intervention (8 sessions over 4 weeks)
Trial: 34842546
Drug: Remote GDMT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remote GDMT titration intervention
Trial: 34842557
Drug: Iowa Gambling
RxNorm normalized name: influenza B virus B/Iowa/06/2017 antigen
DrugBank: Influenza B virus B/Iowa/06/2017 antigen (MDCK cell derived, propiolactone inactivated) (DB15508)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iowa Gambling Task administered via a web app
Trial: 34843044
Drug: Sapanisertib (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sapanisertib (3 mg QD)
Trial: 34843401
Drug: Poziotinib (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Poziotinib (16 mg) once daily
Trial: 34843469
Drug: Fractional-dose 17DD-YF
RxNorm normalized name: Poliovirus, inactivated, fractional-dose (fIPV)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractional-dose 17DD-YF vaccine in ARD patients
Trial: 34843666
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with dexamethasone and anti-IL-6
Trial: 34844283
Drug: Insulin therapy
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin therapy guided by continuous glucose monitoring systems (CGMS)
Trial: 34844283
Drug: Insulin therapy
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin therapy guided by other forms of glucose data collection
Trial: 34844422
Drug: Moderate hyperglycemia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate hyperglycemia (serum glucose levels ≥140 mg/dL-<180)
Trial: 34844422
Drug: Severe hyperglycemia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Severe hyperglycemia (serum glucose levels ≥180 mg/dL)
Trial: 34844770
Drug: Lanreotide Autogel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanreotide Autogel 120 mg (LAN 120 mg)
Trial: 34844977
Drug: Etigilimab alone
RxNorm normalized name: Etigilimab
DrugBank: Etigilimab (DB18854)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etigilimab alone (0.3, 1.0, 3.0, 10.0, 20.0 mg/kg intravenously)
Trial: 34844977
Drug: Etigilimab in
RxNorm normalized name: Etigilimab
DrugBank: Etigilimab (DB18854)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etigilimab in combination with nivolumab (3.0, 10.0, 20.0 mg/kg etigilimab and 240 mg nivolumab)
Trial: 34844980
Drug: Anlotinib +
RxNorm normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib + PD-1 checkpoint inhibitor
Trial: 34844993
Drug: Conventional Treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Treatments
Trial: 34845071
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (MMF) 1,200 mg/m²
Trial: 34845082
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of PCV10 at 24 months (Control group)
Trial: 34845300
Drug: Ranibizumab intravitreal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab intravitreal injections in vitrectomized eyes
Trial: 34845300
Drug: Ranibizumab intravitreal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab intravitreal injections in non-vitrectomized eyes
Trial: 34845300
Drug: Ranibizumab intravitreal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab intravitreal injections (both groups)
Trial: 34845868
Drug: Levetiracetam (1,000-2,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levetiracetam (1,000-2,000 mg daily in two divided doses during CCRT and adjuvant chemotherapy)
Trial: 34845917
Drug: Cluster 3
RxNorm normalized name: CLUSTER FIG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cluster 3 (middle-aged/lowest medication adherence)
Trial: 34845924
Drug: Dietary intake
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary intake of EPA+DHA >200 mg/d
Trial: 34845924
Drug: Dietary intake
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary intake of EPA+DHA ≤50 mg/d
Trial: 34845924
Drug: Dietary intake
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary intake of EPA+DHA per 100 mg/d
Trial: 34846614
Drug: Laparoscopic TME
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laparoscopic TME (L-TME)
Trial: 34848522
Drug: 330 mL/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 330 mL/d of orange juice (OJ)
Trial: 34848522
Drug: Control drinks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control drinks with and without hesperidin (approx. 200-215 mg)
Trial: 34848527
Drug: Immersive virtual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immersive virtual reality (VR) therapy
Trial: 34849677
Drug: IL-6 concentrations
RxNorm normalized name: IL-6
DrugBank: Human interleukin-6 (DB15060)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-6 concentrations ≥ median (17 ng/L)
Trial: 34849728
Drug: Theophylline (starting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (starting dose 300 mg b.i.d.)
Trial: 34851726
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for 48 weeks
Trial: 34852305
Drug: High-intensity bridging
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensity bridging chemotherapy (≥2 cycles)
Trial: 34852305
Drug: Low-intensity bridging
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity bridging chemotherapy (1 cycle)
Trial: 34852305
Drug: Bridging chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bridging chemotherapy (both intensities)
Trial: 34853082
Drug: Optimised preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimised preventive treatment strategy (treating arteries instead of risk factors)
Trial: 34853376
Drug: Single intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous access iohexol GFR measurement
Trial: 34853376
Drug: Single intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous access iohexol GFR measurement after blood discarding and saline flushing
Trial: 34853376
Drug: Blood sampling
RxNorm normalized name: TERUFLEX Blood with Diversion Blood Sampling Arm Anticoagulant CPD with OPTISOL Red Cell Preservative for Collection of 450mL of Blood KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood sampling from a second intravenous access
Trial: 34853511
Drug: Anti-inflammatory anti-diabetic
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-inflammatory anti-diabetic medication (including metformin)
Trial: 34853511
Drug: Metformin-containing therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin-containing therapy
Trial: 34853511
Drug: Oral anti-diabetic
RxNorm normalized name: Diabetic Tussin EX Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anti-diabetic medication (overall)
Trial: 34854079
Drug: high-dose dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: high-dose dexamethasone (HD-DXM)
Trial: 34854079
Drug: standard-dose rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: standard-dose rituximab
Trial: 34854079
Drug: low-dose rituximab
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: low-dose rituximab
Trial: 34854418
Drug: Fresh gas
RxNorm normalized name: Peroxi-Fresh
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fresh gas flow rate at 3 L/min with HME attached
Trial: 34854418
Drug: Fresh gas
RxNorm normalized name: Peroxi-Fresh
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fresh gas flow rate at 6 L/min with HME attached
Trial: 34854418
Drug: Fresh gas
RxNorm normalized name: Peroxi-Fresh
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fresh gas flow rate at 3 L/min without HME
Trial: 34854418
Drug: Fresh gas
RxNorm normalized name: Peroxi-Fresh
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fresh gas flow rate at 6 L/min without HME
Trial: 34854418
Drug: HME (+)
RxNorm normalized name: TRACH-VENT HME TELEFLEX #41112
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HME (+) regardless of anesthetic agent
Trial: 34854418
Drug: HME (-)
RxNorm normalized name: TRACH-VENT HME TELEFLEX #41112
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HME (-) regardless of anesthetic agent
Trial: 34854818
Drug: Vaccination with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccination with the Pfizer vaccine
Trial: 34855649
Drug: Short-term psychopharmacological
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term psychopharmacological treatment (12 weeks)
Trial: 34857214
Drug: Oral Iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Iron Absorption Test (OIAT) combined with Oral Glucose Tolerance Test (OGTT) measuring ΔSeFe after an oral iron dose of 6 mg.
Trial: 34857214
Drug: Fractional Iron
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractional Iron Absorption (FIA) using stable iron isotopes from a labeled iron dose.
Trial: 34857214
Drug: Oral Iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Iron Absorption Test (OIAT)
Trial: 34857432
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy (DAPT) at 396 days post-MI
Trial: 34857432
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy (DAPT) at 5 years post-MI
Trial: 34857432
Drug: DAPT use
RxNorm normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAPT use in relation to age and treatment type
Trial: 34857473
Drug: Management including
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Management including medical treatment and secondary revascularization (SR)
Trial: 34857585
Drug: Octreotide infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide infusion during liver transplantation surgery
Trial: 34857585
Drug: Placebo infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusion during liver transplantation surgery
Trial: 34857658
Drug: urokinase-type plasminogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: urokinase-type plasminogen activator receptor (uPAR) PET/CT
Trial: 34858178
Drug: Immunotherapy combined
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy combined with antiangiogenic therapy
Trial: 34858423
Drug: Dendritic Cell-Based
RxNorm normalized name: Dendritic cells vaccine
DrugBank: Dendritic cells vaccine (DB15803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dendritic Cell-Based HIV Vaccine in combination with Pegylated Interferon α-2a
Trial: 34858523
Drug: Oral glutamine
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral glutamine (gln) powder 15 g bid for the full duration of treatment
Trial: 34858829
Drug: neoadjuvant concurrent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: neoadjuvant concurrent chemoradiotherapy (nCRT)
Trial: 34859113
Drug: Perioperative administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perioperative administration of cefazolin, vancomycin, bacitracin, and cephalexin
Trial: 34860120
Drug: Repository corticotropin
RxNorm normalized name: Repository Corticotropin Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repository corticotropin injection
Trial: 34860418
Drug: High-dose LNF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose LNF (≥75 mg po bid + RTV) for 12 weeks
Trial: 34860418
Drug: All-oral low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All-oral low-dose LNF (25 or 50 mg po bid + RTV) for 24 weeks
Trial: 34860418
Drug: Combination low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Combination low-dose LNF (25 or 50 mg po bid + RTV + PEG-IFNα) for 24 weeks
Trial: 34860739
Drug: Iopromide administration
RxNorm normalized name: Iopromide
DrugBank: Iopromide (DB09156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iopromide administration in children
Trial: 34860739
Drug: Iopromide administration
RxNorm normalized name: Iopromide
DrugBank: Iopromide (DB09156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iopromide administration in elderly
Trial: 34860739
Drug: Iopromide administration
RxNorm normalized name: Iopromide
DrugBank: Iopromide (DB09156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iopromide administration in adults
Trial: 34862245
Drug: Autologous dendritic
RxNorm normalized name: COVID19 s-vax loaded autologous dendritic cell vaccine
DrugBank: COVID19 s-vax loaded autologous dendritic cell vaccine (DB15814)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous dendritic cell vaccine pulsed with lysate derived from a GBM stem-like cell line (given weekly for 4 weeks, then every 8 weeks until depletion or disease progression)
Trial: 34862245
Drug: Autologous dendritic
RxNorm normalized name: COVID19 s-vax loaded autologous dendritic cell vaccine
DrugBank: COVID19 s-vax loaded autologous dendritic cell vaccine (DB15814)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous dendritic cell vaccine pulsed with lysate derived from a GBM stem-like cell line
Trial: 34862302
Drug: Cognitive-behavioural therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioural therapy (CBT) performed by a CBT-trained cardiac nurse plus usual care
Trial: 34863019
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (Folinic Acid and Thyroid Hormone)
Trial: 34863019
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment groups pooled for post-hoc analysis
Trial: 34863025
Drug: IgG3 donor-specific
RxNorm normalized name: Donor Human Stool
DrugBank: Fecal microbiota (DB17743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgG3 donor-specific antibodies (dnDSA) from ABMR+ patients
Trial: 34863025
Drug: IgG3 donor-specific
RxNorm normalized name: Donor Human Stool
DrugBank: Fecal microbiota (DB17743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgG3 donor-specific antibodies (dnDSA) from ABMR- patients